About: SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review
Creator	Chakraborty, Rana Affiliations, Phil, D Theiler, Regan Elrefaei, Amro Ibirogba, Eniola Mbbch, Amro Narang, Kavita Ruano, Rodrigo Teles, Ayssa Garovic, Vesna Gunaratne, Madugodaralalage Ann, Elizabeth Enninga, L Mbbs, Eniola Mbbs, Madugodaralalage Szymanski, Linda Trad, A
source	Elsevier; Medline; PMC
abstract	Abstract The global pandemic of SARS-CoV-2, the cause of Coronavirus disease 2019 (COVID-19), has been associated with worse outcomes in several patient populations, including the elderly and those with chronic comorbidities. Data from previous pandemics and seasonal influenza suggest that pregnant women may be at increased risk for infection-associated morbidity and mortality. Physiological changes in normal pregnancy and metabolic and vascular changes of high-risk pregnancies may affect pathogenesis or exacerbate the clinical presentation of COVID-19. Specifically, SARS-CoV-2 enters the cell via the angiotensin converting enzyme 2 (ACE2) receptor, which is upregulated in normal pregnancy. Upregulation of ACE2 mediates conversion of Angiotensin II (vasoconstrictor) to Angiotensin 1-7 (vasodilator) and contributes to relatively low blood pressures, despite upregulation of other components of the renin angiotensin aldosterone system. As a result of higher ACE2 expression, pregnant women may be at an elevated risk of complications from SARS-CoV-2 infection. Upon binding to ACE2, SARS-CoV-2 causes its downregulation, thus lowering Angiotensin 1-7 levels, which can mimic/worsen vasoconstriction, inflammation, and pro-coagulopathic effects that occur in preeclampsia. Indeed, early reports suggest that, among other adverse outcomes, preeclampsia may be more common in pregnant women with COVID-19. Medical therapy, during both pregnancy and breast feeding, relies on medications with proven safety, but safety data are often missing for medications in the early stages of clinical trials. We summarize guidelines for medical/obstetric care and outline future directions for optimization of treatment and preventive strategies for pregnant patients with COVID-19 with the understanding that relevant data are limited and rapidly changing.
has issue date	2020-05-30(xsd:dateTime)
bibo:doi	10.1016/j.mayocp.2020.05.011
bibo:pmid	32753148
has license	els-covid
sha1sum (hex)	240267e88f730f0530a3e04b45dcc11bca55b84b
schema:url	https://doi.org/10.1016/j.mayocp.2020.05.011
resource representing a document's title	SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review
has PubMed Central identifier	PMC7260486
has PubMed identifier	32753148
schema:publication	Mayo Clin Proc
resource representing a document's body	covid:240267e88f730f0530a3e04b45dcc11bca55b84b#body_text
is schema:about of	named entity 'presentation' named entity 'normal' named entity 'binding' named entity 'vasoconstrictor' named entity 'comorbidities' named entity 'changing' named entity 'result' named entity 'mortality' named entity 'pregnancy' named entity 'clinical trials' named entity 'CLINICAL PRESENTATION' named entity 'VASOCONSTRICTION' named entity 'NORMAL PREGNANCY' named entity 'DATA' named entity 'HIGHER' covid:arg/240267e88f730f0530a3e04b45dcc11bca55b84b named entity 'risk' named entity 'populations' named entity 'high-risk pregnancies' named entity 'missing' named entity 'upregulated' named entity 'levels' named entity 'downregulation' named entity 'outline' named entity 'summarize' named entity 'directions' named entity 'outcomes' named entity 'data' named entity 'proven' named entity 'Physiological' named entity 'vasodilator' named entity 'pregnancy' named entity 'pandemic' named entity 'SARS-CoV-2' named entity 'Mayo Clinic Proceedings' named entity 'Multidisciplinary' named entity 'COVID' named entity 'pregnant women' named entity 'SARS-CoV-2' named entity 'high-risk pregnancies' named entity 'coagulopathic' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'vasoconstriction' named entity 'COVID' named entity 'downregulation' named entity 'pandemics' named entity 'SARS-CoV-2' named entity 'ACE2' named entity 'morbidity' named entity 'renin' named entity 'SARS-CoV-2' named entity 'metabolic' named entity 'ACE2' named entity 'Physiological' named entity 'COVID' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'early stages' named entity 'pregnant women' named entity 'Ang II' named entity 'plasma' named entity 'spike protein' named entity 'enzyme'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software